In this first clinical study to date of an intranasal formulation of ketamine for treatment resistant depression, antidepressant effect was rapid in onset after 1 week of treatment and dose related, finds new double-blind, doubly randomized, delayed-start, placebo-controlled study.

This randomized clinical trial compares the effects of 3 dose levels of intranasal esketamine with placebo in patients with treatment-resistant depression.

About Robert Zinn

Robert Zinn, M.D., Ph.D. is a medical doctor, physician, and web entrepreneur, who, for over 15 years was employed by academic and research institutions and focused his clinical practices on very specialized patient populations, such as those with rare genetic diseases or rare cancers. He shares his knowledge through his website,

View all posts by Robert Zinn →